Pfizer's sickle cell therapy candidate inclacumab failed to demonstrate efficacy in a pivotal Phase 3 trial, according to recent announcements. This failure follows Pfizer's voluntary withdrawal of Oxbryta amid safety concerns, compounding difficulties in expanding therapeutic options for sickle cell disease. The setback represents a critical blow to Pfizer’s investments in this therapeutic area and underscores the challenges in developing effective sickle cell treatments.